Thymulin

Thymulin (originally named Facteur Thymique Sérique, or Serum Thymic Factor) is a nonapeptide exclusively produced by thymic epithelial cells, discovered by Jean-François Bach at the Hôpital Necker in Paris in the 1970s. It is unique among thymic peptides in its absolute requirement for zinc — the apo-peptide (without zinc) is biologically inactive, and only the zinc-coordinated form can bind to its receptor and exert immunomodulatory effects. The zinc ion is coordinated by the asparagine, serine, and glutamine residues in the C-terminal portion of the molecule.

Thymulin levels in circulation decline dramatically with age, paralleling the involution of the thymus gland. Peak levels occur during puberty and decrease to near-undetectable concentrations by age 60. This decline correlates with the age-related deterioration of T-cell-mediated immunity (immunosenescence), making thymulin a biomarker of thymic function and a candidate therapeutic for restoring immune competence in aging. Its zinc dependency also connects thymulin biology to the well-documented effects of zinc deficiency on immune function.

Thymulin binds to high-affinity receptors on T-cell precursors and mature T-lymphocytes, promoting several aspects of T-cell biology. In the thymus, it facilitates the differentiation of immature thymocytes into functional T-cell subsets by modulating expression of T-cell surface markers (CD3, CD4, CD8) and T-cell receptor components. In the periphery, thymulin enhances mature T-cell function, including proliferative responses to mitogens, cytokine production (IL-2, IFN-γ), and cytotoxic activity.

The zinc requirement is structural — Zn²⁺ induces a conformational change that exposes the receptor-binding epitope. This makes thymulin a natural zinc sensor for the immune system: when zinc is depleted, thymulin loses its active conformation and T-cell modulation is impaired, even if thymulin peptide levels are adequate. This explains why zinc supplementation in elderly subjects can partially restore thymulin-dependent immune function without requiring exogenous thymulin administration. Beyond classical immune modulation, thymulin has demonstrated anti-inflammatory effects in the central nervous system, reducing neuroinflammatory cytokines and modulating the HPA axis during sepsis through intranasal delivery that bypasses the blood-brain barrier.